TriangleIrinotecan (NCT05669339)
Irinotecan trial for Hepatocellular Carcinoma (NCT05669339). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults aged eighteen to ninety-nine with advanced hepatocellular carcinoma and Child-Pugh A liver function. Surgery or local treatment alone must be unsuitable or have failed.
The idea: sorafenib and sonidegib block growth signals; irinotecan damages DNA during copying. Patients take the first two drugs orally and receive weekly irinotecan infusions. Researchers escalate doses to find tolerated ranges and collect tumor-DNA and safety data to inform computer-guided individual dosing.
This phase 2 study plans 12 patients. Ali Zarrinpar leads at the University of Florida, Gainesville, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.